JP2023533963A5 - - Google Patents
Info
- Publication number
- JP2023533963A5 JP2023533963A5 JP2023501015A JP2023501015A JP2023533963A5 JP 2023533963 A5 JP2023533963 A5 JP 2023533963A5 JP 2023501015 A JP2023501015 A JP 2023501015A JP 2023501015 A JP2023501015 A JP 2023501015A JP 2023533963 A5 JP2023533963 A5 JP 2023533963A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- formulation
- syringe
- stable pharmaceutical
- aqueous solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063049540P | 2020-07-08 | 2020-07-08 | |
| US63/049,540 | 2020-07-08 | ||
| PCT/US2021/040648 WO2022010988A1 (en) | 2020-07-08 | 2021-07-07 | Stabilized formulations containing anti-ctla-4 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023533963A JP2023533963A (ja) | 2023-08-07 |
| JP2023533963A5 true JP2023533963A5 (enExample) | 2024-07-16 |
Family
ID=77207237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023501015A Pending JP2023533963A (ja) | 2020-07-08 | 2021-07-07 | 抗ｃｔｌａ－４抗体を含む安定化製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220031843A1 (enExample) |
| EP (1) | EP4178983A1 (enExample) |
| JP (1) | JP2023533963A (enExample) |
| KR (1) | KR20230035595A (enExample) |
| CN (1) | CN115812080A (enExample) |
| AU (1) | AU2021305093A1 (enExample) |
| CA (1) | CA3185091A1 (enExample) |
| IL (1) | IL299152A (enExample) |
| MX (1) | MX2022016218A (enExample) |
| WO (1) | WO2022010988A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022015272A2 (pt) | 2020-02-04 | 2022-09-20 | Regeneron Pharma | Teor de umidade residual alvo para produto de fármaco liofilizado |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
| JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
| JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
| JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| JO3417B1 (ar) * | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| NZ609557A (en) * | 2010-10-06 | 2014-12-24 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
| AR087305A1 (es) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| KR102063028B1 (ko) * | 2012-01-23 | 2020-01-07 | 리제너론 파아마슈티컬스, 인크. | 항-ａｎｇ2 항체를 함유하는 안정화된 제형 |
| EP2633874A1 (en) * | 2012-03-02 | 2013-09-04 | Sanofi-Aventis Deutschland GmbH | Fixed-dose medicament delivery device |
| AR092325A1 (es) * | 2012-05-31 | 2015-04-15 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit |
| KR20250004095A (ko) * | 2015-04-17 | 2025-01-07 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물 |
| JP2020518598A (ja) * | 2017-05-02 | 2020-06-25 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 単独およびプログラム死受容体１（ｐｄ−１）抗体と組み合わされた抗ｃｔｌａ４抗体の安定な製剤、ならびにその使用方法 |
| TWI799432B (zh) | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| US20210317220A1 (en) * | 2018-09-24 | 2021-10-14 | Janssen Biotech, Inc. | Method of providing safe administration of an anti-cd154 antibody |
| EP4082572A4 (en) * | 2019-12-25 | 2024-03-06 | Bio-Thera Solutions, Ltd. | ANTI-CTLA-4 MONOCLONAL ANTIBODY, PREPARATION METHOD AND ITS APPLICATION |
-
2021
- 2021-07-07 MX MX2022016218A patent/MX2022016218A/es unknown
- 2021-07-07 IL IL299152A patent/IL299152A/en unknown
- 2021-07-07 KR KR1020237003824A patent/KR20230035595A/ko active Pending
- 2021-07-07 JP JP2023501015A patent/JP2023533963A/ja active Pending
- 2021-07-07 CN CN202180049075.7A patent/CN115812080A/zh active Pending
- 2021-07-07 AU AU2021305093A patent/AU2021305093A1/en not_active Abandoned
- 2021-07-07 WO PCT/US2021/040648 patent/WO2022010988A1/en not_active Ceased
- 2021-07-07 CA CA3185091A patent/CA3185091A1/en active Pending
- 2021-07-07 EP EP21749919.3A patent/EP4178983A1/en active Pending
- 2021-07-07 US US17/369,321 patent/US20220031843A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102667484B1 (ko) | 안정한 항체 제형 | |
| CN103501814B (zh) | 含有抗白介素-4 受体(il-4r)的抗体的稳定制剂 | |
| US20200369760A1 (en) | Stabilized formulations containing anti-angptl3 antibodies | |
| JP2022526292A5 (enExample) | ||
| TW201216983A (en) | Stabilized formulations containing anti-NGF antibodies | |
| JP2022532927A5 (enExample) | ||
| AU2013267301B2 (en) | Stabilized formulations containing anti-Dll4 antibodies | |
| KR20220131923A (ko) | 안정한 항체 제형 | |
| AU2024372916A1 (en) | Stable antibody formulation comprising fianlimab | |
| TWI498121B (zh) | 含有抗－介白素－４受體（ｉｌ－４ｒ）抗體之安定化配製物 | |
| JP2023533963A5 (enExample) | ||
| CN115812080A (zh) | 含有抗ctla-4抗体的稳定调配物 | |
| RU2024135750A (ru) | Составы антитела к рецептору интерлейкина-4 (il-4r) | |
| OA20777A (en) | Stable antibody formulation. | |
| HK1232793A1 (en) | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies | |
| EA042167B1 (ru) | Стабилизированные композиции, содержащие антитела к рецептору интерлейкина-4 (il-4r) | |
| HK1232793B (zh) | 含有抗白介素-4 受体(il-4r)的抗体的稳定制剂 | |
| EA047546B1 (ru) | Стабилизированные составы, содержащие антитела анти-pcsk9 |